Haematological Malignancy

AML, ALL, CML, Hodgkin's, NHL, Myeloma — classification, treatment, TLS prevention, neutropenic sepsis emergency, and GCC haematology centres

Leukaemia Lymphoma Neutropenic Sepsis GCC Context

Leukaemias at a Glance

AML

  • Induction: 7+3 (cytarabine 7 days + anthracycline 3 days)
  • APL (M3): ATRA + arsenic trioxide; DIC risk at diagnosis
  • All-trans retinoic acid (ATRA) — differentiation therapy

ALL

  • Most common childhood cancer
  • Ph+ (BCR-ABL) = poor prognosis; add TKI
  • CNS prophylaxis: intrathecal methotrexate
  • Maintenance: 2 years (6-MP + methotrexate)

CML

  • Philadelphia chromosome t(9;22) — BCR-ABL1
  • Imatinib (TKI) = first-line; excellent response
  • Blast crisis = transformation to acute leukaemia
  • Monitor with BCR-ABL PCR

Lymphomas & Myeloma

Hodgkin's Lymphoma

  • Reed-Sternberg cells (CD15+, CD30+)
  • B symptoms: fever, night sweats, weight loss >10%
  • Ann Arbor staging (I–IV)
  • ABVD: Adriamycin, Bleomycin, Vinblastine, Dacarbazine
  • Excellent prognosis early stage (>90% cure)

NHL — DLBCL

  • DLBCL = most common aggressive NHL
  • R-CHOP: rituximab + cyclophosphamide + doxorubicin + vincristine + prednisolone
  • CNS involvement = poor prognosis

Multiple Myeloma

  • CRAB: hypercalCaemia, Renal failure, Anaemia, Bone disease
  • Paraprotein on SPEP; Bence Jones in urine
  • Bortezomib + lenalidomide + dexamethasone (VRd)
  • ASCT in eligible patients